JP2013518057A - 芳香族カチオン性ペプチドおよびその使用 - Google Patents

芳香族カチオン性ペプチドおよびその使用 Download PDF

Info

Publication number
JP2013518057A
JP2013518057A JP2012550189A JP2012550189A JP2013518057A JP 2013518057 A JP2013518057 A JP 2013518057A JP 2012550189 A JP2012550189 A JP 2012550189A JP 2012550189 A JP2012550189 A JP 2012550189A JP 2013518057 A JP2013518057 A JP 2013518057A
Authority
JP
Japan
Prior art keywords
lys
dmt
arg
peptide
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012550189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518057A5 (cg-RX-API-DMAC10.html
Inventor
ヘイゼル エイチ セトー
ピーター ダブリュー シラー
Original Assignee
コーネル ユニヴァーシティー
アンスティテュ ド ルシェルシュ クリニーク ド モントリオール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー, アンスティテュ ド ルシェルシュ クリニーク ド モントリオール filed Critical コーネル ユニヴァーシティー
Publication of JP2013518057A publication Critical patent/JP2013518057A/ja
Publication of JP2013518057A5 publication Critical patent/JP2013518057A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012550189A 2010-01-25 2011-01-24 芳香族カチオン性ペプチドおよびその使用 Pending JP2013518057A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29806210P 2010-01-25 2010-01-25
US61/298,062 2010-01-25
PCT/US2011/022247 WO2011091357A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015163826A Division JP2016000750A (ja) 2010-01-25 2015-08-21 芳香族カチオン性ペプチドおよびその使用

Publications (2)

Publication Number Publication Date
JP2013518057A true JP2013518057A (ja) 2013-05-20
JP2013518057A5 JP2013518057A5 (cg-RX-API-DMAC10.html) 2014-03-13

Family

ID=44307257

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012550189A Pending JP2013518057A (ja) 2010-01-25 2011-01-24 芳香族カチオン性ペプチドおよびその使用
JP2015163826A Pending JP2016000750A (ja) 2010-01-25 2015-08-21 芳香族カチオン性ペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015163826A Pending JP2016000750A (ja) 2010-01-25 2015-08-21 芳香族カチオン性ペプチドおよびその使用

Country Status (8)

Country Link
US (6) US20120329730A1 (cg-RX-API-DMAC10.html)
EP (4) EP2528934A4 (cg-RX-API-DMAC10.html)
JP (2) JP2013518057A (cg-RX-API-DMAC10.html)
CN (2) CN102834408A (cg-RX-API-DMAC10.html)
AU (2) AU2011207432A1 (cg-RX-API-DMAC10.html)
CA (2) CA2787331A1 (cg-RX-API-DMAC10.html)
HK (1) HK1208686A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011091357A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017052742A (ja) * 2015-09-11 2017-03-16 キユーピー株式会社 抗酸化剤

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3708178T1 (sl) * 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2808029A3 (en) 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
JP2013532124A (ja) * 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CA2858550A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
US20150119552A1 (en) * 2012-04-12 2015-04-30 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
CA2920735A1 (en) * 2013-08-12 2015-02-19 Stealth Biotherapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
CA2932408A1 (en) * 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
JP6854771B2 (ja) * 2015-03-06 2021-04-07 ステルス バイオセラピューティックス コープ 薬学的に適切なペプチドを調製するための方法
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3010321A1 (en) * 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
WO2017156403A1 (en) * 2016-03-11 2017-09-14 Stealth Biotherapeutics Crystalline salt forms
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
EP3681900A4 (en) * 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020131283A1 (en) 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264497A (ja) * 1987-01-02 1988-11-01 メルク　エンド　カムパニー　インコーポレーテッド ヒスチジン置換基を含むレニン阻害物質
JPH04502629A (ja) * 1989-11-06 1992-05-14 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 還元不可逆性ボンベシンアンタゴニスト
JPH06509075A (ja) * 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
JP2006516652A (ja) * 2003-02-04 2006-07-06 コーネル リサーチ ファウンデイション インコーポレイテッド ミトコンドリア透過性転移の阻止方法
JP2007518818A (ja) * 2004-01-23 2007-07-12 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264497A (ja) * 1987-01-02 1988-11-01 メルク　エンド　カムパニー　インコーポレーテッド ヒスチジン置換基を含むレニン阻害物質
JPH04502629A (ja) * 1989-11-06 1992-05-14 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 還元不可逆性ボンベシンアンタゴニスト
JPH06509075A (ja) * 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
JP2006516652A (ja) * 2003-02-04 2006-07-06 コーネル リサーチ ファウンデイション インコーポレイテッド ミトコンドリア透過性転移の阻止方法
JP2007518818A (ja) * 2004-01-23 2007-07-12 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017052742A (ja) * 2015-09-11 2017-03-16 キユーピー株式会社 抗酸化剤

Also Published As

Publication number Publication date
EP2848628A1 (en) 2015-03-18
EP2733150A1 (en) 2014-05-21
AU2011207432A1 (en) 2012-08-02
US20180244721A1 (en) 2018-08-30
US20150005242A1 (en) 2015-01-01
WO2011091357A1 (en) 2011-07-28
HK1208686A1 (en) 2016-03-11
US20130316964A1 (en) 2013-11-28
EP2528934A4 (en) 2013-08-21
EP2528934A1 (en) 2012-12-05
CN104725472A (zh) 2015-06-24
CA2787331A1 (en) 2011-07-28
US20120329730A1 (en) 2012-12-27
EP3018138A1 (en) 2016-05-11
US20190330272A1 (en) 2019-10-31
CN102834408A (zh) 2012-12-19
CA3008993A1 (en) 2011-07-28
AU2016200747A1 (en) 2016-02-25
US20170008925A1 (en) 2017-01-12
JP2016000750A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
US20190330272A1 (en) Aromatic-cationic peptides and uses of same
US20210261613A1 (en) Aromatic-cationic peptides and uses of same
CN116440247A (zh) 治疗线粒体疾病的方法
EP3049096B1 (en) Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
CN115990242A (zh) 预防或治疗巴斯综合征的方法和组合物
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
HK1179977A (en) Aromatic-cationic peptides and uses of same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151202